Tarsus Pharmaceuticals Appoints David Pyott to its Board of Directors
Tarsus Pharmaceuticals has appointed David E. I. Pyott, former chairman and CEO of Allergan, Inc., to its board of directors. Pyott brings extensive global leadership experience in pharmaceuticals, having transformed Allergan into a major specialty pharmaceutical and medical device leader. His appointment is expected to provide invaluable guidance as Tarsus scales its commercial product XDEMVY, advances its pipeline, and aims for sustained growth.
A Look At Tarsus Pharmaceuticals (TARS) Valuation After Adding Former Allergan CEO David Pyott To Its Board
Tarsus Pharmaceuticals' (TARS) shares are gaining attention after former Allergan CEO David E. I. Pyott joined its Board of Directors. Despite recent stock declines of 11.1% over 30 days and 21.7% year-to-date, the company's valuation is considered undervalued at $63.27 compared to an analyst target of $87.50. Analysts project a consensus price target of $76.0, with a range from $45.0 to $92.0, primarily based on expectations of rapid revenue expansion and increased profit margins, though future performance hinges on XDEMVY's continued traction and controlled SG&A expenses.
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
Tarsus Pharmaceuticals has appointed David E. I. Pyott, former Chairman and CEO of Allergan, Inc., to its Board of Directors. Pyott brings extensive leadership experience in the biopharmaceutical industry, having transformed Allergan into a global leader. His expertise is expected to be invaluable as Tarsus scales its product XDEMVY and advances its pipeline in eye care and other therapeutic areas.
Ex-Allergan chief who grew sales to $7B joins Tarsus board
Tarsus Pharmaceuticals has appointed David E. I. Pyott, the former Chairman and CEO of Allergan, to its Board of Directors. Pyott brings 17 years of leadership experience at Allergan, during which he grew the company's sales from approximately $1 billion to over $7 billion, and is expected to provide invaluable expertise for Tarsus's XDEMVY commercialization and pipeline advancement. His appointment aims to strengthen the company's strategic direction, particularly in scaling its lead commercial product and developing its promising pipeline in eye care and beyond.
Former Allergan CEO David Pyott joins Tarsus Pharmaceuticals board
David E. I. Pyott, the former Chairman and CEO of Allergan, Inc., has been appointed to the Board of Directors of Tarsus Pharmaceuticals (NASDAQ:TARS). This move comes as Tarsus, currently valued at $2.66 billion with strong revenue growth, receives a "Strong Buy" consensus from analysts. Pyott's extensive experience transforming Allergan into a global pharmaceutical leader is expected to be invaluable as Tarsus scales its commercialized product XDEMVY and advances its pipeline.
Tarsus Pharmaceuticals Adds Industry Veteran to Board
Tarsus Pharmaceuticals has expanded its board by appointing David E. I. Pyott, former CEO of Allergan, as an independent director. Pyott's extensive experience in eye care and the biopharmaceutical industry is expected to bolster Tarsus' commercial strategies and long-term growth as it scales its product XDEMVY and advances its pipeline. Despite strong technical performance and revenue growth, Tarsus faces financial challenges and valuation concerns, reflected in a current "Hold" rating from analysts and a "Neutral" assessment from TipRanks’ AI Analyst, Spark.
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
Tarsus Pharmaceuticals, Inc. announced the appointment of David E. I. Pyott, former Chairman and CEO of Allergan, Inc., to its Board of Directors. Pyott brings extensive leadership experience in the biopharmaceutical industry, having transformed Allergan into a global specialty pharmaceutical leader. His expertise is expected to be invaluable as Tarsus scales its commercial product XDEMVY, advances its pipeline, and aims for sustained growth in eye care and other therapeutic areas.
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
Tarsus Pharmaceuticals has appointed David E. I. Pyott, the former Chairman and CEO of Allergan, Inc., to its Board of Directors. Pyott brings substantial experience in the biopharmaceutical industry, particularly in eye care, having grown Allergan significantly during his tenure. His expertise is expected to be invaluable as Tarsus scales its product XDEMVY, advances its pipeline, and aims for sustained growth.
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
Tarsus Pharmaceuticals, Inc. announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on Monday, February 23, 2026, via a live webcast. The webcast is scheduled for 1:30 p.m. PT / 4:30 p.m. ET. The company will also make a recorded version of the call available on its website for approximately 90 days following the event.
Tarsus Pharmaceuticals (TARS) Projected to Post Quarterly Earnings on Tuesday
Tarsus Pharmaceuticals (TARS) is expected to report its Q4 2025 earnings before market open on Tuesday, February 24th, with analysts projecting earnings of ($0.19) per share. The company's stock opened at $60.78, down 3.9%, and boasts a market capitalization of $2.58 billion. Insider selling by Dianne C. Whitfield and CEO Bobak R. Azamian in December, while institutional investors hold approximately 90.01% of the shares.
(TARS) Movement as an Input in Quant Signal Sets
This article analyzes Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) using AI-generated quant signals. It identifies a current breakdown, lower price expectations, and elevated downside risk in the long term. The analysis provides specific trading strategies (Long Position, Momentum Breakout, and Risk Hedging Short) with entry, target, and stop-loss levels, along with multi-timeframe signal analysis for support and resistance levels.
TimesSquare Capital Management LLC Invests $15.90 Million in Tarsus Pharmaceuticals, Inc. $TARS
TimesSquare Capital Management LLC has invested $15.90 million in Tarsus Pharmaceuticals, Inc. by purchasing a new stake of 267,505 shares. This investment, valued at approximately $15.9 million, represents about 0.63% of the company, with institutional ownership now standing at 90.01%. Despite some insider selling by CEO Bobak R. Azamian and Dianne C. Whitfield, analysts maintain a "Moderate Buy" rating for Tarsus Pharmaceuticals with a consensus target price of $82.29.
Liquidity Mapping Around (TARS) Price Events
The article provides a detailed liquidity mapping analysis for Tarsus Pharmaceuticals Inc. (NASDAQ: TARS), highlighting divergent sentiment across different time horizons and suggesting choppy market conditions. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating various support and resistance levels. The analysis points to elevated downside risk due to a lack of long-term support signals.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Moderate Buy" by Brokerages
Tarsus Pharmaceuticals (NASDAQ:TARS) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month price target of $79.86 based on nine analyst ratings. Insider selling was noted in late 2025, but institutional investors hold a significant 90.01% stake in the company. The clinical-stage ophthalmic company recently reported strong Q-results, beating revenue and EPS estimates.
Lisanti Capital Growth LLC Has $2.56 Million Position in Tarsus Pharmaceuticals, Inc. $TARS
Lisanti Capital Growth LLC reduced its stake in Tarsus Pharmaceuticals (NASDAQ:TARS) by 43.1% in the third quarter, holding 43,011 shares valued at $2.56 million. Institutional investors and hedge funds collectively own approximately 90% of the company's stock. Analysts have a "Moderate Buy" consensus rating with a $79.86 average price target, despite the company remaining unprofitable and experiencing recent insider selling.
Tarsus prices $125M stock offering
Tarsus Pharmaceuticals has priced an underwritten public offering of 3,125,000 shares of its common stock at $40.00 per share. The gross proceeds are expected to be $125 million, with the company granting underwriters a 30-day option to purchase an additional 468,750 shares. The offering is anticipated to close around February 5, 2024.
Tarsus prices $125M stock offering
The article reports that Tarsus has priced a stock offering totaling $125 million. This indicates a significant financial move by the company to raise capital through the issuance of new shares.
Investors Still Waiting For A Pull Back In Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) currently has a high price-to-sales (P/S) ratio of 7.4x, which is significantly above the industry average for pharmaceutical companies in the United States. This elevated P/S is attributed to the company's strong revenue growth, which increased by 182% last year and is projected by analysts to grow by 38% per year over the next three years, outpacing the industry's 32% annual forecast. Shareholders appear comfortable with this valuation, anticipating continued prosperity based on these strong growth expectations.
Hussman Strategic Advisors Inc. Purchases Shares of 31,500 Tarsus Pharmaceuticals, Inc. $TARS
Hussman Strategic Advisors Inc. recently acquired 31,500 shares of Tarsus Pharmaceuticals (NASDAQ:TARS) worth $1.87 million in the third quarter, bringing institutional ownership to approximately 90.01%. This comes despite recent insider selling by director Dianne C. Whitfield and CEO Bobak R. Azamian. Analysts generally rate Tarsus as a "Moderate Buy" with an average price target of $79.86, and the company recently surpassed revenue and EPS estimates.
Universal Beteiligungs und Servicegesellschaft mbH Has $5.44 Million Stake in Tarsus Pharmaceuticals, Inc. $TARS
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Tarsus Pharmaceuticals, Inc. by 77.0% in Q3, now owning 91,590 shares valued at $5.44 million. Despite insider sales from CEO Bobak R. Azamian and Dianne C. Whitfield, institutional ownership stands at 90.01%, with analysts giving a consensus "Moderate Buy" rating and an average target price of $79.86. Tarsus Pharmaceuticals, a clinical-stage biopharmaceutical company, reported a beat on EPS and revenue for its latest quarter, and its stock currently trades at $67.94.
SG Americas Securities LLC Sells 27,833 Shares of Tarsus Pharmaceuticals, Inc. $TARS
SG Americas Securities LLC significantly reduced its stake in Tarsus Pharmaceuticals by 81.8% in Q3, selling 27,833 shares. This institutional selling aligns with recent insider sales from executives, although institutional investors still hold a large portion of the company's stock. Analysts remain mixed on Tarsus, with a consensus of "Moderate Buy" and an average price target of $79.86, while the stock currently trades around $68.36 with a negative P/E ratio.
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals (TARS) has recently experienced a 16.4% stock decline, but technical indicators and analyst sentiment suggest it's poised for a rebound. Its Relative Strength Index (RSI) of 19.34 signals an oversold condition, while analysts have significantly raised earnings estimates, leading to a Zacks Rank #1 (Strong Buy). These factors indicate the stock may be nearing a reversal point, offering a potential buying opportunity.
Why (TARS) Price Action Is Critical for Tactical Trading
This article analyzes Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) stock, highlighting a weak near and mid-term sentiment that could challenge its long-term positive outlook. It presents multiple AI-generated trading strategies—position, momentum breakout, and risk hedging—along with multi-timeframe signal analysis to guide tactical trading decisions. The analysis also emphasizes the importance of a 62.6:1 risk-reward setup targeting a 17.9% gain against 0.3% risk.
Does Tarsus Pharmaceuticals (NASDAQ:TARS) Have A Healthy Balance Sheet?
Tarsus Pharmaceuticals (NASDAQ:TARS) uses debt but maintains a healthy balance sheet with US$329.6m net cash after accounting for US$72.3m in debt against US$401.8m in cash. Despite operating at an EBIT loss in the last year, the company boasts impressive revenue growth of 182% to US$366m and enough cash to fund operations for at least two more years. This financial position suggests the company is not heavily burdened by debt and has strong potential for future growth.
Does Tarsus Pharmaceuticals (NASDAQ:TARS) Have A Healthy Balance Sheet?
Tarsus Pharmaceuticals (NASDAQ:TARS) has a strong financial position, with US$329.6m in net cash as of September 2025, despite using debt in its business. The company holds US$401.8m in cash and US$72.3m in debt. Although Tarsus Pharmaceuticals is not yet profitable, it grew revenue by 182% to US$366m in the last year, and its substantial cash reserves provide a buffer for continued growth.
While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) has seen a significant 417% increase in its share price over the past three years, driven by 100% annual revenue growth, despite the company currently not being profitable. Although the stock experienced a slight dip of 3.7% in the last seven days, its overall long-term performance suggests strong underlying business growth. The article recommends investors consider closer examination of TARS or adding it to their watchlist due to its impressive historical growth and sustained momentum.
While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) has seen its share price increase by 417% over the last three years, significantly outperforming most loss-making companies with its 100% annual revenue growth. Despite a recent 3.7% dip in the last seven days, the company's strong momentum suggests it warrants a closer look from investors. The article highlights that while the recent dip might be concerning for short-term buyers, the long-term performance indicates robust growth.
BMRN or TARS: Which Is the Better Value Stock Right Now?
BioMarin Pharmaceutical (BMRN) appears to be a better value stock than Tarsus Pharmaceuticals, Inc. (TARS) according to Zacks Equity Research. BMRN holds a stronger Zacks Rank (#2 Buy vs. #3 Hold for TARS) and a superior Value grade of A, as opposed to TARS' D. Key valuation metrics like P/E, PEG, and P/B ratios also indicate BMRN is currently more undervalued.
Understanding Momentum Shifts in (TARS)
This article analyzes momentum shifts for Tarsus Pharmaceuticals Inc. (NASDAQ: TARS), noting weak near- and mid-term sentiment but a strong long-term outlook. It details specific AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report highlights an exceptional risk-reward setup, targeting a 16.2% gain against a 0.3% risk.
Tarsus Pharmaceuticals, Inc. Publishes Corporate Presentation on Eye Care Innovations
Tarsus Pharmaceuticals, Inc. has released a corporate presentation detailing its progress in eye care, highlighting XDEMVY as the sole FDA-approved treatment for Demodex blepharitis with patent protection until 2038. The company reported record Q3 2025 net sales for XDEMVY and plans to begin a Phase 2 study for Lyme disease prevention in 2026, alongside ongoing global expansion efforts.
Insider Sell Alert: Dianne Whitfield Sells 15,565 Shares of Tarsus Pharmaceuticals Inc (TARS)
Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals Inc (TARS), sold 15,565 shares on January 2, 2026, reducing her holdings to 23,393 shares. This transaction is part of a trend of 18 insider sells and no buys over the past year for Tarsus Pharmaceuticals. The stock, trading at $80.67, has a price-to-GF-Value ratio of 0.49, indicating it might be a "Possible Value Trap, Think Twice."
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from Analysts
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has received a consensus "Moderate Buy" rating from nine analysts, with an average 12-month price target of $79.86. Despite recent insider share sales, the company's strong institutional ownership and better-than-expected Q3 earnings ($0.30 EPS loss vs. $0.35 expected; $118.7M revenue vs. $114.22M expected) suggest a positive outlook for investors.
Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Bobak Azamian Sells 6,000 Shares
Tarsus Pharmaceuticals CEO Bobak Azamian sold 6,000 shares of the company's stock for $495,060 on December 24th, reducing his ownership by 0.69%. Following the transaction, Azamian directly owns 857,991 shares worth approximately $70.8 million. The company recently beat revenue and EPS estimates but remains unprofitable; analysts maintain a "Moderate Buy" consensus with an average target price of $79.86.
Tarsus to Participate at the Bank of America 2023 Healthcare Conference
Tarsus Pharmaceuticals, Inc. announced that its CEO and Chairman, Bobak Azamian, M.D., Ph.D., and Chief Financial and Strategy Officer, Jeff Farrow, will participate in 1:1 meetings at the Bank of America 2023 Healthcare Conference on May 10, 2023. The company is advancing several investigational medicines, including TP-03 for Demodex blepharitis, TP-04 for papulopustular rosacea, and TP-05 for Lyme disease prevention. Tarsus focuses on addressing unmet medical needs with scientific and technological advancements, initially in eye care.
Market Sentiment Around Loss-Making Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a loss-making biopharmaceutical company, is projected by analysts to break even and turn a profit of US$91 million in 2026, recuperating from a US$81 million trailing-twelve-month loss. The company's capital management is considered judicious, with low debt contributing to reduced investment risk despite its current unprofitable status. Investors should note the optimistic 63% annual growth rate required for this breakeven prediction, and consider further analysis of the company's fundamentals beyond this overview.
Market Sentiment Around Loss-Making Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
This article analyzes the future prospects of loss-making Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), focusing on when the company is expected to achieve profitability. According to analyst forecasts, Tarsus Pharmaceuticals is projected to break even and turn a profit of US$91m in 2026, driven by an optimistic average annual growth rate of 63%. The company's low debt-to-equity ratio also suggests judicious capital management, reducing investment risk despite its current loss-making status.
Market Sentiment Around Loss-Making Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is nearing profitability, with analysts predicting a final loss in 2025 before achieving a profit of US$91m in 2026. The company, currently with a US$3.5b market cap, needs to grow at an average annual rate of 63% to reach this breakeven target. Its judicious capital management, with debt making up only 22% of equity, reduces risk for investors despite its current loss-making status.
Insider Sell: Dianne Whitfield Sells 7,397 Shares of Tarsus Phar
Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals Inc, sold 7,397 shares of the company on December 16, 2025. This transaction adds to a trend of insider selling at Tarsus Pharmaceuticals, with 16 insider sells and no insider buys over the past year. The stock is currently trading at $80.1, with a price-to-GF-Value ratio of 0.5, suggesting it may be a "Possible Value Trap, Think Twice."
Insider Sell: Dianne Whitfield Sells 7,397 Shares of Tarsus Pharmaceuticals Inc (TARS)
Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals Inc, sold 7,397 shares of the company on December 16, 2025, reducing her holdings to 38,958 shares. This sale is part of a pattern with no insider buys and 16 insider sells over the past year. The stock, trading at $80.1, has a price-to-GF-Value ratio of 0.5, suggesting it might be a "Possible Value Trap, Think Twice" according to GuruFocus.
Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Dianne Whitfield Sells 7,397 Shares
Tarsus Pharmaceuticals (NASDAQ:TARS) insider Dianne Whitfield sold 7,397 shares of the company's stock on December 16, 2025, for a total value of approximately $592,500. This transaction reduced her stake by nearly 16%. The company recently exceeded Q3 EPS and revenue estimates but remains unprofitable, while institutional investors have increased their positions.
Assenagon Asset Management S.A. Has $74.17 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. $TARS
Assenagon Asset Management S.A. significantly increased its stake in Tarsus Pharmaceuticals, Inc. by 25.1% in the third quarter, bringing its total holdings to 1,247,954 shares valued at approximately $74.17 million. This move aligns with increased institutional interest, as other major firms like Driehaus and Norges Bank have also initiated or expanded multi-million dollar positions in TARS. Currently, institutional investors own about 90.01% of the company, which recently exceeded EPS and revenue estimates and carries a "Moderate Buy" analyst rating with an average price target of $79.86.
Squarepoint Ops LLC Boosts Position in Tarsus Pharmaceuticals, Inc. $TARS
Squarepoint Ops LLC significantly increased its stake in Tarsus Pharmaceuticals Inc. in Q2, now owning 102,642 shares valued at $4.16 million, contributing to institutional investors holding 90.01% of the company. Despite beating Q2 earnings and revenue estimates, Tarsus remains unprofitable with negative net margins. Analysts currently have a "Moderate Buy" consensus rating with an average price target of $79.86, while the stock trades around $80.48.
Tarsus Pharmaceuticals chief medical officer talks AI in eye care
Elizabeth Yeu, Chief Medical Officer at Tarsus Pharmaceuticals, discusses the evolving role of AI and big data in eye care, highlighting its potential to enhance diagnostic accuracy and surgical precision. While optimistic about technological advancements, Yeu expresses concern over the shrinking pipeline of ophthalmologists amidst a growing demand for eye care services due to an aging population. Her role involves being the voice of eye surgeons and subject matter experts within the company, finding fulfillment in the real-world impact of their therapies.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of "Moderate Buy" by Analysts
Tarsus Pharmaceuticals (NASDAQ:TARS) has received an average "Moderate Buy" rating from nine analysts, with a 1-year average price target of $79.86. Institutional investors hold approximately 90.01% of the stock, while insiders own 8.97%, and CEO Bobak Azamian recently sold 6,000 shares. The company beat Q3 earnings expectations with an EPS of ($0.30) and revenue of $118.7 million, and its shares are trading near a 1-year high.
Jump Financial LLC Purchases 188,317 Shares of Tarsus Pharmaceuticals, Inc. $TARS
Jump Financial LLC significantly increased its stake in Tarsus Pharmaceuticals (NASDAQ:TARS) by 385.9% in Q2, acquiring 188,317 shares to reach a total of 237,117 shares valued at $9.61 million. This move highlights substantial institutional interest, with major funds recently initiating or expanding positions, bringing institutional ownership to 90.01%. Despite negative earnings, Tarsus Pharmaceuticals reported a revenue beat and holds a "Moderate Buy" consensus rating with an average price target of $79.86.
Norges Bank Acquires Shares of 471,354 Tarsus Pharmaceuticals, Inc. $TARS
Norges Bank has acquired 471,354 shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the second quarter, representing a stake valued at approximately $19.1 million and 1.12% ownership of the company. This move contributes to the already high institutional ownership of about 90.01% in Tarsus Pharmaceuticals. Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $79.86, while the stock recently traded near its one-year high of approximately $82.
Tarsus Pharmaceuticals stock hits all-time high at 83.67 USD
Tarsus Pharmaceuticals Inc. (TARS) stock reached an all-time high of $83.67, with current trading at $83.77, reflecting a significant 63.72% increase over the past year. The company boasts a strong financial position, with a 4.29 current ratio and substantial revenue growth of 182.44%, leading to a "strong buy" consensus among analysts. Recent news includes beating Q3 2025 earnings expectations and Mizuho initiating "Outperform" coverage with a $100 price target, highlighting their approved ophthalmology product, Xdemvy.
Tarsus Pharmaceuticals Leads Six-Month Stock Performance with 85.5% Return
Tarsus Pharmaceuticals has demonstrated remarkable performance over the past six months, leading with an 85.5% return, followed by Broadcom (50.13%) and RF Industries (46.1%). Other strong performers include Kaiser Aluminum and REV Group. The article highlights investor interest in smaller market capitalization stocks, suggesting a trend towards growth opportunities in less established firms across diverse sectors.
Quantbot Technologies LP Purchases 24,319 Shares of Tarsus Pharmaceuticals, Inc. $TARS
Quantbot Technologies LP significantly increased its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 151.8% during the second quarter, acquiring an additional 24,319 shares, bringing its total holdings to 40,339 shares valued at approximately $1.63 million. This comes amidst other institutional investors establishing or growing their positions, pushing institutional ownership to about 90.01%. Despite recent insider selling, analysts maintain a "Moderate Buy" rating for Tarsus Pharmaceuticals, with a consensus target price of $74.14, following the company's modest beat on recent quarterly EPS and revenue estimates.
Tarsus Pharmaceuticals (TARS): Revisiting Valuation After a Strong Multi‑Year Share Price Run
Tarsus Pharmaceuticals (TARS) has seen significant share price appreciation over the past one and three years, despite operating at a net loss. Analysts have a consensus price target of $76.0, with a rich intrinsic fair value of $86.11, suggesting the stock may be undervalued. This positive outlook hinges on continued XDEMVY adoption and controlled marketing and R&D spending.
